Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)

This study is currently recruiting participants.
Verified March 2014 by Cooperative International Neuromuscular Research Group
Sponsor:
Collaborators:
U.S. Department of Education
Parent Project Muscular Dystrophy
Information provided by (Responsible Party):
Cooperative International Neuromuscular Research Group
ClinicalTrials.gov Identifier:
NCT00468832
First received: May 1, 2007
Last updated: March 14, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to establish the largest long-term assessment of people with Duchenne muscular dystrophy (DMD). In this study, the investigators associated with the Cooperative International Neuromuscular Research Group CINRG) will take a detailed look (for a minimum of eight years) at DMD participant's physical abilities, the medical problems they experience, and how they use health care services. Physical abilities will be compared to a group of healthy controls.

The second purpose of this study is to find out whether small, normal differences in the genetic makeup of people with DMD (called "single nucleotide polymorphisms" or "SNPs") affect how their disease progresses and relates to muscle strength/size and steroid response.

The third purpose of this study is to study genetic variations associated with DMD.

The final purpose of this study is to determine whether certain biomarkers are present in people with DMD and not in healthy controls.


Condition
Duchenne Muscular Dystrophy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Longitudinal Study of the Relationship Between Impairment, Activity Limitation, Participation and Quality of Life in Persons With Confirmed Duchenne Muscular Dystrophy (DMD)

Resource links provided by NLM:


Further study details as provided by Cooperative International Neuromuscular Research Group:

Biospecimen Retention:   Samples With DNA

Blood samples are being collected for single-nucleotide polymorphism, Genome-wide Association Study, and biomarker analyses.


Estimated Enrollment: 810
Study Start Date: December 2005
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Ongoing Duchenne Muscular Dystrophy (DMD) Cohort
340 patients currently enrolled participants with DMD.
New Young Duchenne Muscular Dystrophy (DMD) Cohort
Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
Typically Developing Control Cohort
Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   2 Years to 30 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The incidence of DMD is considered equal across racial and ethnic groups. At the start of the CINRG program, it was assumed by investigators that the aggregate subject populations of the participating US sites should closely mirror the racial and ethnic distribution of the US population.

DMD is an X-linked recessive disease affecting only males. However, female carriers of the disease can be symptomatic due to skewed X-inactivation, a secondary genetic event. We have opted to study the most commonly affected population, males, to ensure subject homogeneity. As such, there are no outreach programs planned for women in this study.

Criteria

DMD Subject Inclusion Criteria

  • Affected subjects must be male and between the ages of 2 and 30
  • Affected subjects between the ages of 2 and 4 must have a diagnosis of DMD confirmed by at least one the following OR have an older male sibling that meet at least one of the following criteria:

    • Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical Duchenne dystrophy OR
    • Gene deletion test positive (missing one or more exons) in the central rod domain exons 25-60) of dystrophin, where reading frame can be predicted as 'out-of-frame',and clinical picture consistent with typical Duchenne dystrophy.
    • Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, other) that is expected to preclude production of the dystrophin protein(i.e. nonsense mutation, deletion/duplication leading to a downstream stop codon),with a typical clinical picture of DMD.
  • Affected subjects between the ages of 5 and 30 must either fulfill the above criteria OR show evidence of a dystrophinopathy and clinical picture consistent with Duchenne Muscular Dystrophy

    • Participants who have documented clinical symptoms referable to a dystrophinopathy and direct support of the diagnosis by either (1) a positive DNA analysis for dystrophin mutation, (2) a muscle biopsy demonstrating abnormal dystrophin, or (3) an elevated CK (>5X normal), and X-linked pedigree and an affected family member who meets either criterion (1) or (2) as described above.

NOTE: Determination of the appropriate clinical symptoms consistent with DMD will generally be the responsibility of the clinician. At a minimum this will include progressive loss of function, with additional consideration for other clinical features such as a characteristic gait, a positive Gower sign and calf pseudohypertrophy. When immunostaining of muscle biopsy is used to determining case definition, the clinical reviewer (site PI) should confirm that appropriate testing has ruled out a secondary deficiency of dystrophin. Affected subjects that do not exhibit the above symptoms consistent with DMD should be excluded.

o Muscle weakness prevalent by 5 years of age

- Non-affected adult subjects must be Parent(s) or legal guardian(s) of an eligible affected subject.

DMD Serum Biomarker Inclusion Criteria

  • Participants must meet eligibility criteria for the DMD phenotyping portion of this study
  • For the GC-treatment response cohort, participants must initiate GC treatment within the first year of study participation (i.e. between their first study visit and their one year follow-up visit)

DMD Subject Exclusion Criteria

For those subjects that confirm DMD diagnosis through a clinical picture consistent with DMD

  • Steroid-naïve subjects ambulating past the 13th birthday
  • Steroid users ambulating past the 16th birthday
  • Subjects/families who are unwilling or unable to comply with the protocol study procedures or visits

Controls Subject Inclusion Criteria

  • Male sex
  • Age 6-30 years
  • Able to comply with functional testing instructions

Control Serum Biomarker Inclusion criteria

  • Participants must be male
  • Participants must be free of DMD, other neuromuscular disease, or other significant concomitant illness
  • Participant must be free of glucocorticoid therapy

Control Subject Exclusion Criteria

  • Musculoskeletal disease
  • Musculoskeletal injury within 6 months of enrollment
  • Other concomitant illness that precludes functional testing in the judgment of the investigator or clinical evaluator
  • Completion of enrollment for age cohort
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00468832

Contacts
Contact: Zoe Sund, BSc (hons) 202-476-4110 zsund@childrensnational.org
Contact: Lauren Hache, MS, CGC 412-224-2030 lhache@childrensnational.org

  Show 23 Study Locations
Sponsors and Collaborators
Cooperative International Neuromuscular Research Group
U.S. Department of Education
Parent Project Muscular Dystrophy
Investigators
Study Chair: Craig McDonald, MD University of California, Davis
  More Information

Additional Information:
No publications provided

Responsible Party: Cooperative International Neuromuscular Research Group
ClinicalTrials.gov Identifier: NCT00468832     History of Changes
Other Study ID Numbers: UCD0305
Study First Received: May 1, 2007
Last Updated: March 14, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Muscular Dystrophy, Duchenne
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on April 17, 2014